{"nctId":"NCT00478023","briefTitle":"A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy","startDateStruct":{"date":"2007-05"},"conditions":["Hysterectomy","Postoperative"],"count":854,"armGroups":[{"label":"Morphine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Morphine"]},{"label":"Tapentadol 50 mg immediate release","type":"EXPERIMENTAL","interventionNames":["Drug: CG5503 IR"]},{"label":"Tapentadol 75 mg immediate release","type":"EXPERIMENTAL","interventionNames":["Drug: CG5503 IR"]},{"label":"Tapentadol 100 mg immediate release","type":"EXPERIMENTAL","interventionNames":["Drug: CG5503 IR"]},{"label":"Matched placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Morphine","otherNames":[]},{"name":"CG5503 IR","otherNames":["Tapentadol"]},{"name":"CG5503 IR","otherNames":["Tapentadol"]},{"name":"CG5503 IR","otherNames":["Tapentadol"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female between 18 and 80 years of age;\n* Scheduled to undergo an abdominal hysterectomy with or without bilateral salpingo-oophorectomy due to uterine leiomyomas, or dysfunctional uterine bleeding or endometrial hyperplasia;\n* Anesthesiological and surgical procedures performed according to protocol;\n* Moderate or severe baseline pain following hysterectomy on a Verbal Rating Scale (VRS) within 6 hours following the last possible application of morphine subcutaneous;\n* Pain following hysterectomy of at least 4 on an 11-point Numeric Rating Scale (NRS) within 6 hours following the last possible application of morphine subcutaneous;\n* American Society of Anesthesiologists (ASA) classification I-III.\n\nExclusion Criteria:\n\n* Vaginal hysterectomy;\n* Ongoing or known history of painful endometriosis;\n* Known or suspected chronic pelvic pain syndrome;\n* Previous abdominal or pelvic open surgery;\n* History of seizure disorder or epilepsy;\n* History of alcohol or drug abuse;\n* Evidence of active infections that may spread to other areas of the body;\n* severely impaired renal function, moderately or severely impaired hepatic function,\n* Allergy or hypersensitivity to oxycodone, morphine, fentanyl hydromorphone, heparin, or any compound planned to be used during the anesthesia;\n* Serious complication during surgery and up to randomization;\n* Pre-operative use within 12hours prior to surgery or peri-operative use of non-steroidal anti-inflammatory drugs (NSAIDs);\n* Treated regularly with opioid analgesic or non-steroidal anti-inflammatory drugs (NSAIDs) within 30 days prior to screening;","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.","description":"Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates \"no pain\" and a score of ten indicates \"pain as bad as you can imagine\". Differences calculated as \\[baseline-post baseline\\] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":"41.0"},{"groupId":"OG001","value":"49.0","spread":"39.87"},{"groupId":"OG002","value":"52.4","spread":"41.85"},{"groupId":"OG003","value":"52.9","spread":"40.95"},{"groupId":"OG004","value":"29.0","spread":"44.98"}]}]}]},{"type":"SECONDARY","title":"Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity","description":"Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates \"no pain\" and a score of ten indicates \"pain as bad as you can imagine\". Differences calculated as \\[baseline-post baseline\\] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116.6","spread":"87.10"},{"groupId":"OG001","value":"112.4","spread":"87.32"},{"groupId":"OG002","value":"120.6","spread":"87.35"},{"groupId":"OG003","value":"123.5","spread":"83.50"},{"groupId":"OG004","value":"71.1","spread":"101.17"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":170},"commonTop":["Nausea","Pyrexia","Flatulence","Vomiting","Constipation"]}}}